The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responses
Carcinoma of unknown primary (CUP) is diagnosed when cancer cells are found in the body, but standard tests cannot show where the cancer first started. This can make choosing the most effective treatment difficult. This UK study tests whether a combination of three chemotherapy medicines—epirubicin, cisplatin, and capecitabine (known together as ECX)—can help treat CUP. These drugs are already used to treat several other types of cancer. The study also includes a research part where scientists analyse small tissue samples from biopsies. They want to see if modern laboratory tests can identify the original source of the cancer and discover how tumours respond to treatment. The main goal is to find out if ECX is an effective option for CUP and to help doctors better understand and diagnose this complex condition in the future.
At a glance
What is this study about?
When someone is diagnosed with cancer, doctors usually find the primary tumour first—for example, in the breast, bowel, or lungs. Sometimes, tests discover cancer cells that have spread to other parts of the body, but doctors cannot find the original tumour, even after detailed scans. This is known as carcinoma of unknown primary, or CUP. Because cancer treatments are usually designed around where the disease began, having an unknown primary can make finding the right care plan more challenging.
This phase II trial is exploring whether a three-drug chemotherapy regimen called ECX is an effective treatment for CUP. ECX combines epirubicin, cisplatin, and capecitabine. Doctors want to see how well these medicines work together to shrink tumours, slow cancer growth, and manage symptoms for people living with this diagnosis.
In addition to testing the chemotherapy, the trial has an important laboratory research side. Scientists are studying tumour tissue and body fluids to look for specific patterns and chemical markers. By doing this, they hope to develop better ways to classify CUP tumours and pinpoint their true origin, which could lead to more personalised treatments for future patients.
Key takeaways
- Tests a combination of three chemotherapy medicines (ECX) for cancer of unknown primary.
- Aims to find out how well this treatment controls tumour growth.
- Includes laboratory research to help doctors better identify where hidden cancers start.
- Open to adults aged 18 and over with an unconfirmed primary tumour.
- Participation is voluntary and will not affect your standard NHS care.
Who may be eligible?
This trial is for adults aged 18 and older who have been diagnosed with a carcinoma where the primary starting point is unknown or uncertain, even after thorough hospital investigations and scans.
To join, you must have had a tissue sample (a biopsy) that confirms your cancer is a carcinoma. The study has two parts: a laboratory research part and a treatment part. Depending on your situation and the types of tissue samples available, you may be invited to join one or both parts.
Certain cancers are not eligible for this trial. These include lymphomas (cancer of the lymphatic system), sarcomas (cancers of the bone or soft tissues), and germ-cell tumours. Your hospital care team will review your records to see if this study is an option for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged 18 or older.
- You have a confirmed diagnosis of carcinoma.
- Doctors cannot identify the primary starting point of your cancer after tests.
- Your cancer is not a lymphoma, sarcoma, or germ-cell tumour.
- You have had or are scheduled to have a tissue biopsy.
What does participation involve?
If you join the treatment part of the study, you will receive the ECX chemotherapy combination in planned cycles. Epirubicin and cisplatin are given as an infusion into a vein at the hospital day unit, while capecitabine is taken as tablets at home. You will have regular clinic visits for blood tests, physical checks, and scans (such as CT scans) to see how the cancer is responding. For the laboratory part, researchers will use tissue samples from biopsies you have already had or are having as part of your normal care. Your team will monitor you closely during treatment and follow up on your health afterwards.
Potential risks and benefits
Locations (1)
- Hammersmith HospitalApproximateLondon, England
Common questions
What does carcinoma of unknown primary mean?
It means doctors have found secondary cancer cells in your body, but even after thorough tests, they cannot find the original place where the cancer started.
How is the ECX treatment given?
ECX is a combination of three medicines. Two are given through a drip into your vein at the hospital, and the third is taken as tablets at home.
Will I need to have extra operations to take part?
No major extra surgery is needed solely for the trial. The research part generally uses tissue from biopsies or procedures you are already having as part of your care.
Can I leave the trial if I change my mind?
Yes. You are free to leave the study at any point. You do not need to give a reason, and your usual NHS care will continue as normal.
Do I have to pay to take part in this study?
No. The trial medicines and tests are provided through the clinical trial and the NHS at no cost to you.
How to find out more
Harpreet Wasan
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.